From candidate to default: the company has just been placed inside buyers' own purchasing systems
The model's full reasoning — Q2 2016 call → NOWe need to determine if management describes a recent transition into an approved/specified/listed status that will unlock future volume without discrete selling events, and that this is new enough that most volume is ahead. Scan transcript for such descriptions. Key points: - Karnes facility licensed as family residential center in Texas. "During the month of May, the State of Texas approved our license application making the Karnes Residential Center the first licensed family residential facility in the State of Texas." This is a licensing approval, which is a form of being approved/listed. But is it a buyer-side system? It's a regulatory license, not a procurement pathway. However, it might be a qualification to operate. But does it mean future business arrives without selling? Not exactly. It's a license to operate, not a status that inserts into a purchasing system. Also, there is a legal case pending. Management says "While there is currently a legal case pending regarding the state's licensing process, we're very proud that our Karnes center was the first to be licensed..." This is not about being placed into a buyer's procurement system. It's about regulatory approval to operate. Not the same as being on a preferred supplier list. - CAR 16 procurement: They submitted proposals, decision expected. That's pending, not yet approved. - ICE Houston procurement: decision could be made in Q3. Pending. - Grafton Prison: shortlisted, proposals due. Pending. - John Morony: shortlisted, proposals due. Pending. - No mention of being added to a formulary, network, or approved supplier list that will automatically generate orders. - The only "approved" status is the Texas license for Karnes, but that's a regulatory license, not a buyer-side system. Also, the facility already operates under a contract with ICE. The license doesn't change the purchasing pathway; it's a compliance requirement. Management does not say that this license will cause future business to flow without selling. They mention it as a point of pride, but not as a gateway to automatic orders. - Also, the ISAP program: they are ahead of schedule, but that's an existing contract with utilization increasing. Not a new status. Thus, no description of a recent transition into an approved/specified/listed status that will unlock future volume without discrete selling events.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| WRBY | Warby Parker Inc. | Q1 2024 | 2024-05-09 | A |
| AZEK | The AZEK Company Inc. | Q2 2024 | 2024-05-08 | B+ |
| DXCM | DexCom, Inc. | Q4 2023 | 2024-02-08 | B+ |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| INGN | Inogen, Inc. | Q1 2023 | 2023-05-05 | F |
| HBB | Hamilton Beach Brands Holding Company | Q3 2022 | 2022-11-05 | C |
| EVGO | EVgo, Inc. | Q2 2022 | 2022-08-09 | C+ |
| OPK | OPKO Health, Inc. | Q1 2022 | 2022-05-09 | D |
| MGNI | Magnite, Inc. | Q1 2022 | 2022-05-04 | D |
| AGIO | Agios Pharmaceuticals, Inc. | Q3 2018 | 2018-11-01 | C |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
PRIM · Q2 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this shift for the newly acquired T&D segment: after the Willbros acquisition (closed June 1, 2018), the T&D Group gained access to major utilities that had been hesitant due to prior financial concerns. With Primoris as parent, they signed new awards from the 3 largest electrical utilities (one announced MSA, two not yet announced), allowing work to flow under existing relationships without repeated persuasion. Management explicitly ties this to the recent acquisition and notes the MSA backlog now at $1.1 billion (first time exceeding $1 billion), with one-year estimated MSA revenue at $1.1 billion and continued growth expected.
AGIO · Q3 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this transition for TIBSOVO. Steve Hoerter states that the company launched in July 2018 and is now receiving reimbursement with “no payer-related coverage issues,” with the payer mix (60% Medicare, 35% commercial) reflecting routine placement in those systems. He further notes that initial prescriptions are being written by over 100 unique prescribers and that awareness is already above 90%, confirming the product has moved from candidate status into the reimbursement and purchasing pathways. Because the launch is only a few months old at the time of the call, the $4.
AZEK · Q2 2024 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, etc...YES The transcript shows management describing recent and incremental shelf-space gains in both pro and retail channels as a new development that will support growth in 2025, with investments planned for Q4 to enable these gains. This is framed as moving beyond prior years' steady execution into fresh wins that create a tailwind for future 2025 volume, where the company is now positioned to benefit from expanded availability in buyer systems (catalogs, dealer networks, and retail displays) without needing to re-persuade for each order.